WallStreetZenWallStreetZen

NASDAQ: HEPA
Hepion Pharmaceuticals Inc Stock

$1.02-0.03 (-2.86%)
Updated Jul 19, 2024
HEPA Price
$1.02
Fair Value Price
N/A
Market Cap
$5.58M
52 Week Low
$0.90
52 Week High
$9.71
P/E
-0.11x
P/B
0.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.52M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.13
Operating Cash Flow
-$36M
Beta
0.66
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

HEPA Overview

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HEPA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HEPA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HEPA is good value based on its book value relative to its share price (0.74x), compared to the US Biotechnology industry average (6.22x)
P/B vs Industry Valuation
HEPA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HEPA due diligence checks available for Premium users.

Be the first to know about important HEPA news, forecast changes, insider trades & much more!

HEPA News

Valuation

HEPA fair value

Fair Value of HEPA stock based on Discounted Cash Flow (DCF)
Price
$1.02
Fair Value
$3.67
Undervalued by
72.21%
HEPA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HEPA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.11x
Industry
-18.27x
Market
29.62x

HEPA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.74x
Industry
6.22x
HEPA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HEPA's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.9M
Profit Margin
0%
HEPA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$16.0M
Liabilities
$8.5M
Debt to equity
1.13
HEPA's short-term assets ($15.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HEPA's short-term assets ($15.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HEPA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HEPA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.6M
Investing
$0.0
Financing
$1.8M
HEPA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HEPA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
HEPA$5.58M-2.39%-0.11x0.74x
SNPX$5.54M+4.42%-0.16x0.25x
PBM$5.52M-3.96%-41.20x-0.34x
PYPD$5.67M-2.00%0.20x-2.71x
RNAZ$5.49M-4.71%-0.00x1.20x

Hepion Pharmaceuticals Stock FAQ

What is Hepion Pharmaceuticals's quote symbol?

(NASDAQ: HEPA) Hepion Pharmaceuticals trades on the NASDAQ under the ticker symbol HEPA. Hepion Pharmaceuticals stock quotes can also be displayed as NASDAQ: HEPA.

If you're new to stock investing, here's how to buy Hepion Pharmaceuticals stock.

What is the 52 week high and low for Hepion Pharmaceuticals (NASDAQ: HEPA)?

(NASDAQ: HEPA) Hepion Pharmaceuticals's 52-week high was $9.71, and its 52-week low was $0.90. It is currently -89.5% from its 52-week high and 13.33% from its 52-week low.

How much is Hepion Pharmaceuticals stock worth today?

(NASDAQ: HEPA) Hepion Pharmaceuticals currently has 5,473,126 outstanding shares. With Hepion Pharmaceuticals stock trading at $1.02 per share, the total value of Hepion Pharmaceuticals stock (market capitalization) is $5.58M.

Hepion Pharmaceuticals stock was originally listed at a price of $20,720.02 in Feb 11, 2014. If you had invested in Hepion Pharmaceuticals stock at $20,720.02, your return over the last 10 years would have been -100%, for an annualized return of -62.91% (not including any dividends or dividend reinvestments).

How much is Hepion Pharmaceuticals's stock price per share?

(NASDAQ: HEPA) Hepion Pharmaceuticals stock price per share is $1.02 today (as of Jul 19, 2024).

What is Hepion Pharmaceuticals's Market Cap?

(NASDAQ: HEPA) Hepion Pharmaceuticals's market cap is $5.58M, as of Jul 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Hepion Pharmaceuticals's market cap is calculated by multiplying HEPA's current stock price of $1.02 by HEPA's total outstanding shares of 5,473,126.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.